<SEC-DOCUMENT>0001935979-23-000033.txt : 20230512
<SEC-HEADER>0001935979-23-000033.hdr.sgml : 20230512
<ACCEPTANCE-DATETIME>20230512164718
ACCESSION NUMBER:		0001935979-23-000033
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20230512
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230512
DATE AS OF CHANGE:		20230512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Biohaven Ltd.
		CENTRAL INDEX KEY:			0001935979
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41477
		FILM NUMBER:		23916645

	BUSINESS ADDRESS:	
		STREET 1:		215 CHURCH STREET
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
		BUSINESS PHONE:		203-404-0410

	MAIL ADDRESS:	
		STREET 1:		215 CHURCH STREET
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Biohaven Research Ltd.
		DATE OF NAME CHANGE:	20220629
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bhvn-20230512.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:e731018d-8906-419f-9d0e-7f68f7316c08,g:22a24c24-5cf3-49f2-9ff0-9d57830eeb8c,d:7be77102a47f4a849bc5975f21cc1863--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bhvn-20230512</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M180L2ZyYWc6NWVkYWVlYWE3MDI0NDc3YmEyM2QwNGU1ZmNhZTRkZmQvdGFibGU6MzEzMDZhZjliMzc1NGYyYTlmMWY5MGVhMWMxZmVjZTEvdGFibGVyYW5nZTozMTMwNmFmOWIzNzU0ZjJhOWYxZjkwZWExYzFmZWNlMV8wLTEtMS0xLTI5NTk1Ng_453b8a05-a767-4bad-8bd6-2565b400f766">0001935979</ix:nonNumeric><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M180L2ZyYWc6NWVkYWVlYWE3MDI0NDc3YmEyM2QwNGU1ZmNhZTRkZmQvdGFibGU6MzEzMDZhZjliMzc1NGYyYTlmMWY5MGVhMWMxZmVjZTEvdGFibGVyYW5nZTozMTMwNmFmOWIzNzU0ZjJhOWYxZjkwZWExYzFmZWNlMV8xLTEtMS0xLTI5NTk1Ng_7a23c9d3-0801-44a3-83a7-abe979cd0db6">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bhvn-20230512.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001935979</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-12</xbrli:startDate><xbrli:endDate>2023-05-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7be77102a47f4a849bc5975f21cc1863_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzI3_e4de2994-2fbd-440c-a5b7-b9485f848907">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8yMjE_96fcfbf5-2e6e-4f09-b3bc-d36924b4dcda">May&#160;12, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzI5_ab5d83f5-473b-4690-bee2-1b6e462a8ab8">Biohaven Ltd.</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGFibGU6OWY4NzcxNzAwMzQxNDg2YWI5NmNiYWY3OTdiYTk5NTEvdGFibGVyYW5nZTo5Zjg3NzE3MDAzNDE0ODZhYjk2Y2JhZjc5N2JhOTk1MV8wLTAtMS0xLTI5NTk1Ng_48446d76-9d30-43a3-897f-646e89d7ae2f">British Virgin Islands</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGFibGU6OWY4NzcxNzAwMzQxNDg2YWI5NmNiYWY3OTdiYTk5NTEvdGFibGVyYW5nZTo5Zjg3NzE3MDAzNDE0ODZhYjk2Y2JhZjc5N2JhOTk1MV8wLTEtMS0xLTI5NTk1Ng_60b9fd7b-bc76-40e7-8065-ae70a60b5b56">001-41477</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Not applicable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzMw_de6313c6-bd9e-4a6f-994f-9e472c201ee9">c/o Biohaven Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzMx_510704c7-b5c3-4301-ab83-88cc0ea12b1a">215 Church Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzIz_f0d08b82-9171-41c8-a257-b8e0fae29ea7">New Haven</ix:nonNumeric>, <ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzM3_b5dee7c5-175d-4219-9d3f-85e59bfe70b7">Connecticut</ix:nonNumeric> <ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzM0_6677e965-0e29-41a2-9663-4827e9f3b3d9">06510</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzMy_f2a6c730-d19e-403d-a136-42caa86a0c64">203</ix:nonNumeric>) <ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzI0_91231236-06b2-44f1-b989-5a3c4836d9fd">404-0410</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzI4_ccf9abb2-5ac5-4140-bb36-a6dd3f8ba0f2">&#9744;</ix:nonNumeric>&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzMz_ba551c61-4402-4386-bc23-5a72f0f0d0cb">&#9744;</ix:nonNumeric>&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzM1_e01d2a9a-da0e-49f2-9efe-93656e241c40">&#9744;</ix:nonNumeric>&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzI1_cc056a5f-471c-40ae-be56-a753654b221b">&#9744;</ix:nonNumeric>&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:37.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.649%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading symbol</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGFibGU6OTUxMzE5YzMzYzFlNDg3ZWEyNzlkMTgzNWUxMDExN2YvdGFibGVyYW5nZTo5NTEzMTljMzNjMWU0ODdlYTI3OWQxODM1ZTEwMTE3Zl8xLTAtMS0xLTI5NTk1Ng_6177dd2f-fdfb-4010-aa24-e701ed85f56a">Common Shares, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGFibGU6OTUxMzE5YzMzYzFlNDg3ZWEyNzlkMTgzNWUxMDExN2YvdGFibGVyYW5nZTo5NTEzMTljMzNjMWU0ODdlYTI3OWQxODM1ZTEwMTE3Zl8xLTEtMS0xLTI5NTk1Ng_5c85c1d8-6c59-4ec7-bb8a-5b5d2ad784d2">BHVN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGFibGU6OTUxMzE5YzMzYzFlNDg3ZWEyNzlkMTgzNWUxMDExN2YvdGFibGVyYW5nZTo5NTEzMTljMzNjMWU0ODdlYTI3OWQxODM1ZTEwMTE3Zl8xLTItMS0xLTI5NTk1Ng_288654d9-13e0-4ece-9a27-da752b4c8fdd">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzI2_ca410ac5-a0da-421c-8c93-11d35877a87b">&#9746;</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzM2_d3d58d09-3980-4237-a4e0-5e82d635dc5a">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7be77102a47f4a849bc5975f21cc1863_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;12, 2023, Biohaven Ltd. (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registrant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) issued a press release announcing its financial results for the first quarter ended March 31, 2023. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant&#8217;s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i7be77102a47f4a849bc5975f21cc1863_10"></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">(d) Exhibits </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:19.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.857%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023q1bhvnltdearningsprex.htm">Press Release, dated  May 12, 2023, "Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments."</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page of this Current Report on Form 8-K formatted as Inline XBRL.</span></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2</span></div></div></div><div id="i7be77102a47f4a849bc5975f21cc1863_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Date: May&#160;12, 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:139%">     </span></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.038%"><tr><td style="width:1.0%"></td><td style="width:14.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Biohaven Ltd.</span></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Matthew Buten</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew Buten</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="text-align:right"><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a2023q1bhvnltdearningsprex.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i93ddfb6c83bc40fd940677268d0b4e65_1"></div><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><font><br></font></div><div id="i93ddfb6c83bc40fd940677268d0b4e65_4"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments </font></div><div><font><br></font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.5pt">Acquired exclusive license for oral, brain-penetrant, dual TYK2&#47;JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.5pt">Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug Administration </font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.5pt">Taldefgrobep alfa granted Fast Track Designation in SMA</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.5pt">Driving strong and consistent progress across six robust drug development platforms in 2023&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">in Kv7 activation, targeting Phase 2&#47;3 study start in focal epilepsy and bipolar disorder in the second half of 2023&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Phase 1 study initiation planned with potentially first-in-class TYK2&#47;JAK1 brain-penetrant inhibitor in immune-mediated brain disorders&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">three Phase 3 studies gaining momentum with regulatory engagement and enrollment completion expected in programs spanning glutamate modulation in SCA and OCD, respectively, and enrollment ongoing in myostatin inhibition program in SMA&#59; </font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">three IND submissions anticipated in 2023 spanning Kv7 activation, TRPM3 antagonism, and IgG degradation offer potential to drive long-term value creation beyond 2023</font></div><div style="margin-top:3pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">NEW HAVEN, Conn., May&#160;12, 2023 &#47;PRNewswire&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#8211; Biohaven Ltd. (NYSE&#58; BHVN) (&#34;Biohaven&#34; or the &#34;Company&#34;), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating neurological and neuropsychiatric diseases, including ultra-rare disorders, today reported financial results for the first quarter ended March 31, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, &#34;We have set forth ambitious goals for the balance of 2023, as we continue advancing what we believe is one of the most innovative and exciting neuroscience platform in development. We were energized by the preliminary safety, tolerability and pharmacokinetic data we reported from our SAD&#47;MAD Phase 1 study of Kv7.2&#47;Kv7.3 activator BHV-7000 earlier in the quarter, supported by the preponderance of preclinical efficacy data generated to date with BHV-7000 demonstrating potent anti-seizure efficacy, concentration-dependent hyperpolarization of the resting membrane potential, meaningful increases in action potential threshold, and encouragingly low GABA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:1.55pt;vertical-align:baseline">A </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">activity. We also look forward to unlocking Kv7 platform expansion opportunities across a spectrum of indications with high unmet medical need.&#34;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Dr Coric continued, &#34;With our glutamate platform, we look to gain clarity on the regulatory path forward for SCA and expect to complete enrollment in our Phase 3 OCD program in 2023, which we believe are two critically important milestones given the dearth of approved therapies for these distinct patient populations. Regarding our myostatin platform, we continue to activate sites and drive enrollment in our ongoing Phase 3 SMA study. With our recently acquired TYK2&#47;JAK1 platform, we remain focused on starting Phase 1 studies in 2023 and exploring BHV-8000's potential to address an array of immune-mediated brain disorders. And finally, we look forward to submitting IND applications across three separate programs, including BHV-7010, a next-gen Kv7 activator targeting epilepsy and mood disorders, BHV-2011, a TRPM3 inhibitor targeting chronic pain, and BHV-1300, our IgG degrader, following the report of robust preclinical data earlier in the year. We remain as committed as ever to driving data-driven, efficient results for patients and the shareholders who support our continued work, and look forward to executing and delivering continued value in the year ahead.&#34;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">First Quarter 2023 and Recent Business Highlights</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Acquired BHV-8000, a brain-penetrant inhibitor of TYK2&#47;JAK1, from Highlightll </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">- As previously reported, in March 2023, the Company acquired exclusive rights (excluding China) to a novel, oral, first-</font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">in-class, brain-penetrant, dual inhibitor of TYK2&#47;JAK1 offering wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2&#47;JAK3 inhibitors. The Company expects to commence Phase 1 development in 2023, exploring its potential to address immune-mediated brain disorders.   </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:13.8pt">Delivered oral and poster presentations demonstrating preclinical efficacy and initial Phase 1 safety and tolerability of BHV-7000 on ASENT 2023 virtual platform - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In March 2023, the Company presented data at the 2023 American Society for Experimental Neurotherapeutics Annual Meeting (ASENT 2023) demonstrating that activating Kv7.2&#47;7.3 with BHV-7000, a structurally and pharmacologically distinct compound from ezogabine, produced concentration-dependent hyperpolarization of the resting membrane potential, potentiated meaningful increases in action potential threshold, exhibited significantly lower GABA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:1.55pt;vertical-align:baseline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> activity than ezogabine, and delivered potent anti-seizure efficacy in the maximal electroshock seizure (MES) model, without negatively impacting neurobehavior. The Company also presented data from the Phase 1 SAD&#47;MAD clinical trial, demonstrating BHV-7000 was well-tolerated at single doses up to 100 mg and multiple doses up to 40 mg per day for 15 days. Most adverse events were mild and resolved spontaneously, and there were no serious or severe adverse events or dose-limiting toxicities reported. In BHV-7000 treated subjects in the MAD study, CNS-related adverse events typically associated with other anti-seizure medications were not reported.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Taldefgrobep Alfa Granted Fast Track Designation and Orphan Drug Designation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- As previously reported, Taldefgrobep alfa, an anti-myostatin adnectin in development for SMA, was granted Fast Track designation and Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in February 2023, and December 2022, respectively. Phase 3 studies are ongoing&#59; the Company expects to enroll approximately 180 patients in this randomized, double-blind, placebo-controlled global trial. </font><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Reported preclinical data with extracellular target degrader platform technology (MoDE&#8482;), a pan-IgG degrader </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As previously reported, in January 2023, the Company evaluated the effect of a single dose of IgG degrader, BHV-1300, in cynomolgus monkeys. The Company reported 75% reduction of IgG levels from baseline and noted the observation occurred in three days&#59; the data in this pre-clinical study compares favorably to standard of care therapy efgartigimod, where reduction of IgG levels with efgartigimod was observed to be 50% and had taken 5-7 days. The Company expects BHV-1300 will be ready for IND submission in the second half of 2023. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Reported preclinical data with second MoDE in bispecific platform targeting IgA Nephropathy </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">- As previously reported, in January 2023, the Company reported preclinical data with a second MoDE targeting galactose deficient IgA (Gd-IgA), which is believed to play a pathogenic role in IgA Nephropathy. Specific removal of pathogenic Gd-IgA with preservation of normal IgA potentially permits disease remission without incurring an infection risk. The Company shared preliminary data demonstrating the chimeric antibody-ASGPR ligand conjugate specifically mediated endocytosis of Gd-IgA, as opposed to normal IgA, in an endocytosis assay with HepG2 cells.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Leadership team expanded with key appointment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> - In April 2023, Biohaven announced the appointment of Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the FDA. Dr. Kozauer had supervised and reviewed the approval of over 15 marketed drugs during his tenure at the FDA. </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Upcoming Expected Milestones&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Biohaven is progressing its product candidates through clinical programs in a number of common and rare disorders. The Company expects to reach significant pipeline milestones in the coming periods. Biohaven expects to&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:14.15pt">Initiate EEG study with BHV-7000 in the first half of 2023&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> Following Phase 1 study completion, Biohaven expects to initiate pivotal trials in patients with epilepsy and patients with bipolar disorder in the second half of 2023.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:14.15pt">Submit IND with BHV-7010 in epilepsy and mood disorders&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Company expects to submit an IND with next-generation Kv7 activator BHV-7010 in epilepsy in the second half of 2023.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:14.15pt">Submit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">IND with BHV-2100 in chronic pain&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Company expects to submit an IND with BHV-2100, a TRPM3 antagonist in the Company's ion channel platform targeting a pain disorder in the second half of 2023. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:14.15pt">Submit IND with BHV-1300&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> The Company expects to submit an IND with pan-IgG degrader BHV-1300 in the second half of 2023.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:13.8pt">Commence Phase 1 studies with BHV-8000&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> The Company expects to commence Phase 1 studies with BHV-8000, an oral, brain-penetrant, dual TYK2&#47;JAK1 inhibitor for immune-mediated brain disorders in 2023.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Complete enrollment in Phase 3 study of troriluzole in OCD in 2023&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Two Phase 3 randomized, double-blind, placebo-controlled studies are expected to enroll up to 700 patients (in each trial) across nearly 200 global study sites. The Company anticipates completing enrollment in year-end 2023.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:14.15pt">Provide an update on troriluzole in SCA&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> The Company intends to interact with the FDA and&#47;or European Medicines Agency in the first half of 2023 on next steps.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:14.15pt">Continue advancing Phase 3 clinical studies of taldefgrobep alfa in SMA&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Company expects to enroll approximately 180 patients in the study through patient enrollment in up to 60 clinical sites.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:14.15pt">Continue advancements across multiple neuroscience and immunoscience indications&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Company's preclinical pipeline includes molecular degraders of extracellular proteins, CD38 targeting antibody recruiting molecules (ARMs), TRP channels, and other undisclosed targets, including those with disease-modifying potential. </font></div><div><font><br></font></div><div id="i93ddfb6c83bc40fd940677268d0b4e65_7"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;text-decoration:underline">Capital Position&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Cash, cash equivalents and marketable securities as of March 31, 2023 was $392.0 million, including $4.0 million of restricted cash, and excluding $61.5 million of cash payable to</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Biohaven Pharmaceutical Holding Company Ltd. (the &#8220;Former Parent&#8221;), compared to $467.9 million, including $2.5 million of restricted cash, and excluding $35.2 million of cash payable to the Former Parent, as of December 31, 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">First Quarter 2023 Financial Highlights&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Research and Development (R&#38;D) Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> R&#38;D expenses, including non-cash share-based compensation costs, were $63.5 million for the three months ended March 31, 2023, compared to $70.1 million for the three months ended March 31, 2022. The decrease of $6.6 million was primarily due to a decrease of $14.7 million in personnel-related costs including non-cash share-based compensation costs, and a decrease in expenses for verdiperstat, BHV-2100 and BHV-1200, partially offset by an increase in expenses for our clinical programs for Kv7 (BHV-7000 and 7010), troriluzole and BHV-2000. The decrease in personnel-related costs is due to non-cash share-based compensation expense for the first quarter of 2022 being allocated from the Former Parent equity plan based on equity awards with higher grant date fair values, which was partially offset by increased personnel </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> On May 9, 2022, the Board of Directors of the Former Parent approved and directed Former Parent&#8217;s management to effect the spin-off of the Kv7 ion channel activators, glutamate modulation and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure then owned by Former Parent in connection with the sale of the Former Parent to Pfizer. On October 3, 2022, the purchase of the Former Parent by Pfizer was consummated and Former Parent completed the distribution to holders of its common shares of all of the outstanding common shares of Biohaven Ltd.</font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">costs related to an increase in headcount for our discovery operations.  Non-cash share-based compensation expense was $2.2 million for the three months ended March 31, 2023, a decrease of $22.3 million as compared to the same period in 2022. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">General and Administrative (G&#38;A) Expenses&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">G&#38;A expenses, including non-cash share-based compensation costs, were $14.3 million for the three months ended March 31, 2023, compared to $19.7 million for the three months ended March 31, 2022. The decrease of $5.4 million was primarily due to decreased non-cash share-based compensation costs. This was partially offset by increased personnel costs in the first quarter of 2023 compared to the same period in 2022, due to a majority of the personnel costs in the first quarter of 2022 being allocated to the Former Parent. Non-cash share-based compensation expense was $1.5 million for the three months ended March 31, 2023, a decrease of $14.1 million as compared to the same period in 2022. The decrease in non-cash share-based compensation expense is due to the first quarter of 2022 expense being allocated from the Former Parent equity plan based on equity awards with higher grant date fair values.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Other Income (Expense), Net&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> Other income (expense), net was a net income of $8.2 million for the three months ended March 31, 2023, compared to net expense of $4.0 thousand for the three months ended March 31, 2022. The increase of $8.2 million was primarily due to an increase in net investment income and an increase of $3.9 million in other income related to our transition services provided to our Former Parent, which is largely non-recurring.</font></div><div style="margin-top:3pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Net Loss&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> Biohaven reported a net loss for the three months ended March 31, 2023, of $70.5 million, or $1.03 per share, compared to $97.0 million, or $2.46 per share, for the same period in 2022. Non-GAAP adjusted net loss for the three months ended March 31, 2023 was $66.7 million, or $0.98 per share, compared to $56.9 million, or $1.45 per share for the same period in 2022. These non-GAAP adjusted net loss and non-GAAP adjusted net loss per share measures, more fully described below under &#8220;Non-GAAP Financial Measures,&#8221; exclude non-cash share-based compensation charges. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below. For periods prior to Biohaven's spin-off from the Former Parent on October 3, 2022 (the &#34;Spin-Off&#34;), net loss per share and non-GAAP adjusted net loss per share were calculated based on the 39,375,944 common shares of Biohaven distributed to the Former Parent shareholders at the time of the distribution, including common shares issued in connection with the Former Parent share options that were settled on October 3, 2022 and common shares issued in connection with the Former Parent restricted share units that vested on October 3, 2022.  The same number of shares is being utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off.</font></div><div><font><br></font></div><div id="i93ddfb6c83bc40fd940677268d0b4e65_13"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States (GAAP), and also certain non-GAAP financial measures. In particular, Biohaven has provided non-GAAP adjusted net loss and adjusted net loss per share, which are adjusted to exclude non-cash share-based compensation, which is substantially dependent on changes in the market price of common shares. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. However, Biohaven believes the presentation of non-GAAP adjusted net loss and adjusted net loss per share, when viewed in conjunction with GAAP results, provides investors with a more meaningful understanding of ongoing operating performance and can assist investors in comparing Biohaven's performance between periods. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, these non-GAAP financial measures are among those indicators Biohaven uses as a basis for evaluating performance, and planning and forecasting future periods. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between these non-GAAP measures and the most directly comparable GAAP measures is provided later in this news release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Biohaven </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's experienced management team brings with it a track record of delivering new drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia. The company is advancing a pipeline of therapies for diseases with little or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia, myostatin inhibition for neuromuscular diseases, and brain-penetrant TYK2&#47;JAK1 inhibition for immune-mediated brain disorders. Biohaven's portfolio of early- and late-stage product candidates </font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and extracellular target degrader platform technology (MoDE&#8482;) with potential application in neurological disorders, cancer, and autoimmune diseases.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-looking Statements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including &#34;continue&#34;, &#34;plan&#34;, &#34;will&#34;, &#34;believe&#34;, &#34;may&#34;, &#34;expect&#34;, &#34;anticipate&#34; and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including&#58; the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials&#59; the timing of planned interactions and filings with the FDA&#59; the timing and outcome of expected regulatory filings&#59; complying with applicable U.S. regulatory requirements&#59; the potential commercialization of Biohaven's product candidates&#59; the potential for Biohaven's product candidates to be first in class therapies&#59; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled &#34;Risk Factors&#34; and &#34;Management's Discussion and Analysis of Financial Condition and Results of Operations&#34;. The forward-looking statements are made as of the date of this new release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i93ddfb6c83bc40fd940677268d0b4e65_16"></div><hr style="page-break-after:always"><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">BIOHAVEN LTD.</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">(Amounts in thousands, except share and per share amounts)</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">(Unaudited)</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:130%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.601%"><tr><td style="width:1.0%"></td><td style="width:65.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.642%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,461&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,096&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,321&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,677&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,782&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,773&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,782)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,773)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,229&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,229&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,553)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,777)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,255&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,492)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,032)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share &#8212; basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.03)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.46)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#8212; basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,206,879&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,375,944&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i93ddfb6c83bc40fd940677268d0b4e65_19"></div><hr style="page-break-after:always"><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">BIOHAVEN LTD.</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">(Amounts in thousands)</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,031&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,877&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,998&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,464&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,400&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,945&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivable</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,830&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,139&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash held on behalf of Former Parent</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,548&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,212&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,669&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,331&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544,476&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586,968&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,494&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,512&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,400&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,400&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,761&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,513&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,521&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,783&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,456&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,703&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to Former Parent</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,548&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,212&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,002&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,106&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,006&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,021&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liability</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,760&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,581&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,410&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,263&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,012&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' Equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred shares, no par value&#59; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2023 and December 31, 2022</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares, no par value&#59; 200,000,000 shares authorized as of March 31, 2023 and December 31, 2022&#59; 68,212,479 and 68,190,479 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,246&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615,742&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,462&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,869&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,616)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,124)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472,258&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,771&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,521&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,783&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i93ddfb6c83bc40fd940677268d0b4e65_22"></div><hr style="page-break-after:always"><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">BIOHAVEN LTD.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">(Amounts in thousands, except share and per share amounts)</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">(Unaudited)</font></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.172%"><tr><td style="width:1.0%"></td><td style="width:74.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.388%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of GAAP to Non-GAAP adjusted net loss&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,492)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,032)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add&#58; non-cash share-based compensation expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,120&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP adjusted net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,727)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,912)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of GAAP to Non-GAAP adjusted net loss per share &#8212; basic and diluted&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP net loss per share  &#8212; basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.03)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.46)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add&#58; non-cash share-based compensation expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP adjusted net loss per share &#8212; basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.98)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.45)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i93ddfb6c83bc40fd940677268d0b4e65_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">MoDEs is a trademark of Biohaven Therapeutics Ltd.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investor Contact&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Jennifer Porcelli</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Vice President, Investor Relations</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">jennifer.porcelli&#64;biohavenpharma.com</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">+1 (201) 248-0741</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media Contact&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Mike Beyer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Sam Brown Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">mikebeyer&#64;sambrown.com</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">+1 (312) 961-2502</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>bhvn-20230512.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e731018d-8906-419f-9d0e-7f68f7316c08,g:22a24c24-5cf3-49f2-9ff0-9d57830eeb8c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bhvn="http://www.biohavenpharma.com/20230512" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biohavenpharma.com/20230512">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhvn-20230512_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhvn-20230512_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.biohavenpharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>bhvn-20230512_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e731018d-8906-419f-9d0e-7f68f7316c08,g:22a24c24-5cf3-49f2-9ff0-9d57830eeb8c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_221435d4-2b52-47d1-b88b-ca4ba2d1e4e0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_70c78839-c795-4726-a2a1-affb8609e5e1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_78cc902c-15ed-4382-8e3c-8547d44a4529_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d7b001da-3812-4973-a598-b8b48f2c5ed6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1cdc8e90-a25b-4007-b226-147f5c405ca9_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_dbed0bbc-bacd-4968-b6af-ddef72a7d551_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_27d3e9e6-434d-4388-982b-0e24d5b21cc2_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b956d369-24fe-4783-a072-810862db93c2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4b8f2d5a-0369-43f7-af86-bcb77f119037_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_42595897-4544-4429-980f-c9d44b0de94b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a13acdf6-e81a-440b-9af6-ca0a397e77a1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_8b5267c4-9a51-4e24-a9c7-453cf91a9fcd_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8cdfbe2b-df42-4096-80d6-58088d9878eb_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9145290e-6247-48b0-abaf-b9103dd59938_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_fe81ff40-e811-4c40-b196-ad729182917e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_934ff304-0057-405f-9d7c-345e4753b5ee_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f3ea4c07-8e55-4003-b2bd-626f639fc666_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8c942b28-60bc-40c8-a9df-8f01a5da80d3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3baae0d3-a967-49d1-a535-e02ac74f319d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_70dfb661-36b8-40b1-8e3b-56ead5921ac5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b1f6d2e6-e43f-40bf-a128-bf316cebe3e9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_85dad5f3-680e-48a1-8a6e-7b310c69e66d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_16689f0e-9873-4768-8abd-0f72d1fad1e8_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>bhvn-20230512_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:e731018d-8906-419f-9d0e-7f68f7316c08,g:22a24c24-5cf3-49f2-9ff0-9d57830eeb8c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/Cover" xlink:type="simple" xlink:href="bhvn-20230512.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.biohavenpharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9a6a8fbe-7634-4b74-b2e8-f1ca5fcdce86" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_DocumentType_9a6a8fbe-7634-4b74-b2e8-f1ca5fcdce86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e58971b6-6451-459c-b471-8b86d46630b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_EntityRegistrantName_e58971b6-6451-459c-b471-8b86d46630b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_388f8691-8e05-4f2c-93b3-491a41e6032f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_DocumentPeriodEndDate_388f8691-8e05-4f2c-93b3-491a41e6032f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_64c8d00e-409b-4911-8868-5490ad657916" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_EntityIncorporationStateCountryCode_64c8d00e-409b-4911-8868-5490ad657916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7a58502e-3b43-4bd6-afd4-a9b626fba690" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_EntityFileNumber_7a58502e-3b43-4bd6-afd4-a9b626fba690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9b26d822-92c2-4699-ace4-612cd66fb12e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_EntityAddressAddressLine1_9b26d822-92c2-4699-ace4-612cd66fb12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_efd750bb-549e-4b31-a36f-ac05ba67b61d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_EntityAddressAddressLine2_efd750bb-549e-4b31-a36f-ac05ba67b61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_73ed17f8-3a10-4cbf-95fa-9d6d0a09b36a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_EntityAddressCityOrTown_73ed17f8-3a10-4cbf-95fa-9d6d0a09b36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2c500bc3-5d05-4d09-b524-238517e6832e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_EntityAddressStateOrProvince_2c500bc3-5d05-4d09-b524-238517e6832e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_454ad6c1-d615-4f12-a445-438b7789b591" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_EntityAddressPostalZipCode_454ad6c1-d615-4f12-a445-438b7789b591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5ee1871b-8711-4457-ab67-7edd3ff960d7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_CityAreaCode_5ee1871b-8711-4457-ab67-7edd3ff960d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b597a330-2d61-4955-a7ed-62a18b51a0a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_LocalPhoneNumber_b597a330-2d61-4955-a7ed-62a18b51a0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_cb27498d-26cc-4c03-880b-9cd395899634" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_WrittenCommunications_cb27498d-26cc-4c03-880b-9cd395899634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_8ad3c3c2-d6b1-44f0-8eaf-d1b7695b8476" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_SolicitingMaterial_8ad3c3c2-d6b1-44f0-8eaf-d1b7695b8476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_d4e35a69-247d-456e-a6cf-1b2746ab5d2c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_PreCommencementTenderOffer_d4e35a69-247d-456e-a6cf-1b2746ab5d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_6703b067-334a-4670-bdad-858c8598af55" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_6703b067-334a-4670-bdad-858c8598af55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8236291a-f59a-4d3f-9f1c-fe0280e916e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_Security12bTitle_8236291a-f59a-4d3f-9f1c-fe0280e916e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9017de19-96f0-408a-bd7b-a2d81851a702" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_TradingSymbol_9017de19-96f0-408a-bd7b-a2d81851a702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6f40bfee-c445-48ea-b4d3-19eebb128aa0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_SecurityExchangeName_6f40bfee-c445-48ea-b4d3-19eebb128aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e5386856-e3ea-49ad-b2d4-f3d33185d85f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_EntityEmergingGrowthCompany_e5386856-e3ea-49ad-b2d4-f3d33185d85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_f2e03324-1cc8-4333-b6e5-247c46642224" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_EntityExTransitionPeriod_f2e03324-1cc8-4333-b6e5-247c46642224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6492701b-325b-40c3-ae64-a37e8ef638f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_EntityCentralIndexKey_6492701b-325b-40c3-ae64-a37e8ef638f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a2b6d591-d22b-4f8d-ba94-6bb610f7f96e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ef9a78c-19df-4a50-ae9a-bedb81e70918" xlink:to="loc_dei_AmendmentFlag_a2b6d591-d22b-4f8d-ba94-6bb610f7f96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140234010699200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Biohaven Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 12,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">D8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">c/o Biohaven Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">215 Church Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">404-0410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BHVN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001935979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>bhvn-20230512_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bhvn-20230512.xsd" xlink:type="simple"/>
    <context id="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001935979</identifier>
        </entity>
        <period>
            <startDate>2023-05-12</startDate>
            <endDate>2023-05-12</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M180L2ZyYWc6NWVkYWVlYWE3MDI0NDc3YmEyM2QwNGU1ZmNhZTRkZmQvdGFibGU6MzEzMDZhZjliMzc1NGYyYTlmMWY5MGVhMWMxZmVjZTEvdGFibGVyYW5nZTozMTMwNmFmOWIzNzU0ZjJhOWYxZjkwZWExYzFmZWNlMV8wLTEtMS0xLTI5NTk1Ng_453b8a05-a767-4bad-8bd6-2565b400f766">0001935979</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M180L2ZyYWc6NWVkYWVlYWE3MDI0NDc3YmEyM2QwNGU1ZmNhZTRkZmQvdGFibGU6MzEzMDZhZjliMzc1NGYyYTlmMWY5MGVhMWMxZmVjZTEvdGFibGVyYW5nZTozMTMwNmFmOWIzNzU0ZjJhOWYxZjkwZWExYzFmZWNlMV8xLTEtMS0xLTI5NTk1Ng_7a23c9d3-0801-44a3-83a7-abe979cd0db6">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzI3_e4de2994-2fbd-440c-a5b7-b9485f848907">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8yMjE_96fcfbf5-2e6e-4f09-b3bc-d36924b4dcda">2023-05-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzI5_ab5d83f5-473b-4690-bee2-1b6e462a8ab8">Biohaven Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGFibGU6OWY4NzcxNzAwMzQxNDg2YWI5NmNiYWY3OTdiYTk5NTEvdGFibGVyYW5nZTo5Zjg3NzE3MDAzNDE0ODZhYjk2Y2JhZjc5N2JhOTk1MV8wLTAtMS0xLTI5NTk1Ng_48446d76-9d30-43a3-897f-646e89d7ae2f">D8</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGFibGU6OWY4NzcxNzAwMzQxNDg2YWI5NmNiYWY3OTdiYTk5NTEvdGFibGVyYW5nZTo5Zjg3NzE3MDAzNDE0ODZhYjk2Y2JhZjc5N2JhOTk1MV8wLTEtMS0xLTI5NTk1Ng_60b9fd7b-bc76-40e7-8065-ae70a60b5b56">001-41477</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzMw_de6313c6-bd9e-4a6f-994f-9e472c201ee9">c/o Biohaven Pharmaceuticals, Inc.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzMx_510704c7-b5c3-4301-ab83-88cc0ea12b1a">215 Church Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzIz_f0d08b82-9171-41c8-a257-b8e0fae29ea7">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzM3_b5dee7c5-175d-4219-9d3f-85e59bfe70b7">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzM0_6677e965-0e29-41a2-9663-4827e9f3b3d9">06510</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzMy_f2a6c730-d19e-403d-a136-42caa86a0c64">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzI0_91231236-06b2-44f1-b989-5a3c4836d9fd">404-0410</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzI4_ccf9abb2-5ac5-4140-bb36-a6dd3f8ba0f2">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzMz_ba551c61-4402-4386-bc23-5a72f0f0d0cb">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzM1_e01d2a9a-da0e-49f2-9efe-93656e241c40">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzI1_cc056a5f-471c-40ae-be56-a753654b221b">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGFibGU6OTUxMzE5YzMzYzFlNDg3ZWEyNzlkMTgzNWUxMDExN2YvdGFibGVyYW5nZTo5NTEzMTljMzNjMWU0ODdlYTI3OWQxODM1ZTEwMTE3Zl8xLTAtMS0xLTI5NTk1Ng_6177dd2f-fdfb-4010-aa24-e701ed85f56a">Common Shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGFibGU6OTUxMzE5YzMzYzFlNDg3ZWEyNzlkMTgzNWUxMDExN2YvdGFibGVyYW5nZTo5NTEzMTljMzNjMWU0ODdlYTI3OWQxODM1ZTEwMTE3Zl8xLTEtMS0xLTI5NTk1Ng_5c85c1d8-6c59-4ec7-bb8a-5b5d2ad784d2">BHVN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGFibGU6OTUxMzE5YzMzYzFlNDg3ZWEyNzlkMTgzNWUxMDExN2YvdGFibGVyYW5nZTo5NTEzMTljMzNjMWU0ODdlYTI3OWQxODM1ZTEwMTE3Zl8xLTItMS0xLTI5NTk1Ng_288654d9-13e0-4ece-9a27-da752b4c8fdd">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzI2_ca410ac5-a0da-421c-8c93-11d35877a87b">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZTc3MTAyYTQ3ZjRhODQ5YmM1OTc1ZjIxY2MxODYzL3NlYzo3YmU3NzEwMmE0N2Y0YTg0OWJjNTk3NWYyMWNjMTg2M18xL2ZyYWc6M2FiYjJkMDRiMmE5NDIxZTk3OWMyYTJkYzI1ODcyYjkvdGV4dHJlZ2lvbjozYWJiMmQwNGIyYTk0MjFlOTc5YzJhMmRjMjU4NzJiOV8xNzM2_d3d58d09-3980-4237-a4e0-5e82d635dc5a">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
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MYHOA/UY_ 5!+ 0(4 Q0    ( .B%K%8'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ Z(6L5OS+OQ;O
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ Z(6L5IE<G",0!@  G"<  !,              ( !S0$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #HA:Q6286K24P$   1$0
M&               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ Z(6L5I^@&_"Q @  X@P   T              ( !D P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " #HA:Q6EXJ[',     3 @  "P
M        @ %L#P  7W)E;',O+G)E;'-02P$"% ,4    " #HA:Q6JL0B%C,!
M   B @  #P              @ %5$   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ Z(6L5B0>FZ*M    ^ $  !H              ( !M1$  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ Z(6L5F60>9(9 0
MSP,  !,              ( !FA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  Y!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="bhvn-20230512.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biohavenpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0547-EntityTaxIdentificationNumber-Missing] Submission type 8-K should have a non-empty value for EntityTaxIdentificationNumber in the Required Context. bhvn-20230512.htm </Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="bhvn-20230512.htm">bhvn-20230512.htm</File>
    <File>a2023q1bhvnltdearningsprex.htm</File>
    <File>bhvn-20230512.xsd</File>
    <File>bhvn-20230512_lab.xml</File>
    <File>bhvn-20230512_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bhvn-20230512.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "bhvn-20230512.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bhvn-20230512_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bhvn-20230512_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bhvn-20230512.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "bhvn",
   "nsuri": "http://www.biohavenpharma.com/20230512",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhvn-20230512.htm",
      "contextRef": "ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.biohavenpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhvn-20230512.htm",
      "contextRef": "ic62fd14083b043f59e3fedfee2ae0b81_D20230512-20230512",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001935979-23-000033-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001935979-23-000033-xbrl.zip
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MQDJQ\PSX&"3XE&0T2N=??FKW3G9"7+-3,,0U.L5!7*M:)\P!E/]]TP7,A&"
M(ZL8+ 28BA#1^77"01%++=N$Y4;6'/X+YA8B9^2A*!8SVQ&S8$XX']HSS^%^
MK&BU$ T$4(/%)L"I*#P56OLE6I\,K1)S=84ST$FA+04A\)?K@IR\M<,)FWG(
MGV M.Z OT9@&D%9,AP./9JVK!0LL96T!AN\QMDI,/RFFPXDOA.)4R:,VO'$,
M*$ .GGHH5:.IQ+>?V$G"'?.QB"THX8+AXTC'W9O.'$'$(G[,P%8"E (^28AS
MD,O!#"A(6LM1R*> <GB+A?-J17LZH#F_G)X9\,H YP##WID;BZ\"7>'A3/#0
M=.Z!9 F1G"1M$;'*=RKM382TFTU54M+&E/3I\HP%T7!J!V@5H_\<VJ8]XXH,
MR&&*26!1=5Q_^WK1Q$?XV ,[>"HQ_FG\ 70\8-*2-.*-1J ;8N'#0@_L '+]
M@" JX,M/V0UW(B%C2/C$4,Q1@>#+-\3_T3KO_?[?GM'.)L?L\OQ/]G'PQ_FE
MP4X]UZV"[\/GO_Q4[]1.Z@U#0IW$\==O\,;@%IP8^IB?)W?TEBECE,6!F<^A
M567'E_^Y.B>KC;W[^,?E*W;\RT_-UHD>1!_ L2?#@#Z<@L#A[IS^?@44H]UP
M4[E[%1 ,8P'&A3>;<'_*31&%Y ::\D&T1*( R-.3U@9H'O+H0=Y8"XXB/#$5
M/L:'[+\U+3+''HF*.>'N&$D:9O#Y#&4H!A)FP@-A**6G)8:V8Y.0&C-7N8JT
M$)R:O@!#R)R %O1M$Y<A0"@'!K"-CB-$#NC/BL]]D>A',+@\B\]!4F*0"K8Q
MBF-8OHIAC12X2$>S_ZJ EP!19JDX1K,NB40R',C-&QM_Y##%C0WHAFWZ,OC%
M31+P=C"182\<G^;Q: :_D^H PRX(/5<$U0<PT! \,?#3(M>J*+H<T?].GHM*
M_W"X!3P%&)'Q!&"P";>!C%S:^NG$%B-V_D.8$2HIY>]3=$!3K"')!MU+0U+L
MGX+A+V#7AH@;H T^)945@>;UN)-@#.@8<"FTU6M@!.)6H',$5 02CELWB&L
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MT$ [UU=A0I 2J&E!] 4 *F5*+H0?EH4Q\%F9QG,20YF"-=)*2L=K,':E(QM
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M/2;@AYKM>?[,HV9GMCORN>Z 0"=IP&*[=66+SBPHZ#G75:7P<1 P "]A.>P
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M=Z)YF=E,W9$#!"GO:==M;-1&9)I0?M!+ _Y"+1J @SC&,U,"(49&!TD=W:D
MMQ? OOX&!("9:W,9M='@1YS%I>4\J6N59GT*F/%K:2, RA#3B3YV;:86R[*[
MD+36#6K>)^_,TXU)R,M8O(+>Y#/92=]6; T#046+$/MSI7*F"1(64[*IY"M)
MQ/1Q?\*J"RBFGNYTAZ/JV[\B?4M)IV& (+P!J@(010[=?1*?U"5H@H'M@24E
M0&T3A$/^P^;&\L0O3DGKF$:!*@^.28ON<5^X5F;I43D]T;UW3*15J.<#]!S;
MHRID/)94D?<UP9.**9>TBRE3I45)E9*]'GL-21K4U[5JJ1*A6(+*D^D+Y0H9
M,L2&?/%]9:=GE69O6>VYD6ZCF-2AXRQQ(?]T#FP\I0;3ZGEB[[@_'I:MGYT&
MKW35Z8,ZXJH#SO'=":GKX608.2704Y>XF6@/^<H!BD)/,E#,@KOH_"+9 ^_E
MM6L5O(,-A2.Y?73LHB"FP?6BE97R@Q?6'L1K)UQKMTWZ'#K*]-67MRE>):7M
MG^&?L22$;X)H:"";[=;[_;;4=9%,(6CG]Q:H(Z-3* 2GKZ>C#^IB3+2ATY^Q
M6VSZL_+;TE]-^3S]41YU2G^3G/N4UW.31K$!]L 6,%KI;UQ?D#&X;71L[=%\
M#>#0==>>%:>(((7CJ-0&;UIQUSV<!D@*%WY\XR6E':7OD%+A!D8!M9N1\*=T
MM^E[W9!OI0F7-0A2A5#*[1A'G'K1RY!EXK[$'J+GQ[$4>7?/#5XWD0X.4$-0
M^2NV120Z0.JI(K%$22PF8W3*\>HB", KB V\\HJAU>#+B(,*_$J?34)H-5F3
M4R1?A!NYX?*NBQ$WE2^LP"\K+*AS='P6F6"L;\>61ZOD^9\HQ Q8)IB+RA^=
M/U5^I5WS[)4AJ>;."H'8K54]ID^0RLLWZ>).)S%BU8G2.Q.DUB-//JG%IZZ(
M5?/(1ZD2;"YO$,,H@Q3IZ+_1S0&IQWQ!M]$1&)/7)M2VE*S2X+ACZ"R;!;7;
MVH>4WRMS[_(J7+J55)G)<D[MG,JR0KQ[4ZA(C;I#ZKZE 4VJT '>OQ9?:JO)
M9)GOO1C;7D>$Q+XZ<P//IM9R!\LI,8L;./\A@VIX>D4UXDU+C938#H0B'O#_
M,59/HNX;\"![+[>1R#[ZZR+VF7[%[J%@*<LVOU21!'"8JVZZ2<3WU'.MY$JY
M;XK]8<B7N$R,9I8:X!Z 3+DEU,D6U>U<.4!2>VGEI2YXC7,F'L %!11%P[#M
M.(E8;^AHA8175,L3Y/?)WMN)D/?)9&4$OMQV2=#)6)*2?LEM.)0'O[5Q<>#@
MB%F(4RA^H=I0A]_N=@"V*!;_%LF)SE&.;L)"28 "0T\?'):5UGCEF/"?_Y![
M$_?Q[M.7CX,_SB_9Y^NS>TL:"KC^TR^79^>75^=G#/ZZ^O+YT]G@&CY<7<,_
M%^>7UU?LRWOVY>OYM\'U)QBPASL\'DPQW:.R%K(>)X@Y.\D*IW+$\H%7^[C9
MWUT.F@-,A,=8_7IA]JA0>-CAU*:\(JO>J<7U..J\;N8<"KS?X;- O-%_G(#7
MBMWXW]@NS4</+3F7LG"V@_8I?U9"K=^L=FIUE&LA0"RT](N5R*N2R'L=6G=_
MZ[2KO69]Y<^UZJZ_M?NMG9Y<MU@\'M;O/<%B6\WV4RRVTVIL.BV01##C[C^/
MFD=ZG"8.U\-C/$48^9JHRU_UB.HA\:8Q^\'J67[$MA)WCB@1!3^ZI*K=6T1W
MEUO7P$%OJH9;6@:R_B;[E_+H>2"P>#1K.0"NJ;SM0I:WG6?+VS8 2TE(CTY(
MR5"E+^@<8GQH$;=R4A 2VQ V6"6Y 63NW^[+@EGCR?DO!YXNWH(/;V2)@MQ'
MEBC(?62)@MQ'EBC(?62)@MQ'WH."(3>_CWTO<JV*,BY-4XC1:)W!NLS] 9/W
MR6W5NP? T%;]$I<&BV6]E-99Z_?M?1.+?]4<C^-/%'Z%>T?PQ5OPX8W<6N:,
MZ'^+,H?1O[4B"Y],A[=4C<=.TF<!"HO<MPWT:JSP<OOG11AMM;_TOGR<M3@;
MZS2-5J>^/"2W"P=LNM>2UEX>K75K1JW?*12M'8 Z>H@)O*K5>_\)^KIO1B/I
M-DP\TX9IH>+D*>S0QG9@7BI+"L9S]9;1;&PKWY>3U-/)]Y>,G[[1Z78+A9\#
MD(GK3/1^D77_-=W)Z]V)$CR%B;X16ZDY5KK?B^G"?>"Y;M?H]AJ[V2$; R)/
M@_C%8K;7-[K=YOY@]@!$[;Y%8#]3QRH\LI+T4GW2\.L&1LM!\>"Q%*^OMK5F
MBB%92ZRNP*H4K7N!U0.0JLL-V(V=^IR26TN;>"ZY_^1);)T-YMB(&!_R@B(M
M<N^XH'@+/KR1)0IR'UFB(/>1)0IR'UFB(/>1)0IR'UFB(/>1+SS?NN;BA3+A
MNE,(VF@T^H7*YY7H2<>Q6EN'L,HHU1-%J9:*PGHO-UFHDJ]/(A'+C-WCB<LR
M%;L'B-U&T)89V!P-TAS3L$/L52ED8_(@[N\K)6_(?RQ>95$F\AZ#+SM]H]W>
MCT1>B=7MTK/=O<#J 8C<O4S/?GT*,?N(YL^^\5R_N:/ANH^VZ;XAIVLTVNU"
MH>< Q-Y>6IJ7ZDJHI[,E=U:RAWLR;;N=%UB.''=K1JO_B-6,A;&52ZH]8*KM
M=XU:<P^H=N^48O$6?'@C2Q3D/K)$0>XC7TY?DLN[EWGC]>CUQLG=.Z'SZ%62
MTHI- *CE1=BI_+!-H2VW7F1;J%ZM;1'NWF[C16Y[4I+M7I-MH]KJ[ '9'H#B
M7%/G4VS%^2=]P"O.Z*)9NM VN= =[R'3UY,_KCY]FBS<UD*J8!S;Z1F-6L?H
M=7<L_RN"RBDQNPRSS;[1[+:-?JNU+YC=.ZE<O 4?WL@2!;F/+%&0^\@2!;F/
M+%&0^\@2!;F/)!2\IAL,WQ[$S;/]H[?ES;/CEW;S[+O!Y\'EZ3F[^GA^?GTP
M]\T6Y3;6Y[T5%1BN6I-,M\.UJ(U.?^7/#[@6M?4DUZ+VNT]RA^M3+7:S:U$W
MO"5R@^Y!.PS-^;; WD:7!<8W=K(-KUH\5$"<"5-,A\+7L,A>H5@2TGWP6W9Q
M]Z-"(3/T@-IR+@?G( A$^+2-.#>88Z<K49=&:)_H1M2-PM4;7[!;PG(76#[K
M::$\TAVGD>^#O&6<>'+W"\H>L2GBGI-,";$G9[)U2?QFH;F-!_)&+A/_$/^-
M[!ON /L]B3+<!GP;%P8]T^W?CU3=OUT!4*Y[JS?:1JWYK+>WQ/LMJ>ZE4EVC
MUC)ZSWLG39;J'K7RN="R_X+[WX4*\0DS\NW0SO^NE]VJ<_(EV4[#Z/=[SWG>
M=S=!^=+15#-:G6V+J!X130><]7RY6SL@7^"K+V;<MAYV[5?NW1USEC$&_+#W
M)O.A8ZEF]%O;]N<H3<P=(/TI[O/#?&$*^P:MS=+$W!J.K:;1:VXK5TH+\[FQ
MU#'JS]N6Z8%R96]-E6\B"'W;Q--'%+B<",=BGLN&8L*=$?-&[+WG3X7/OG),
M)I26S-80[M2-=FM;G[:T9)X92\VVT:AO>YEL:<GL?%6!F4E.EH;,]J9WR^AT
M<E21)98VO!>^N77FIWB&3'&EB6SV_PC2I-@MB7,EXG:K9;2ZG0<?FGVLUL2Y
MVS<'A^!>Q^AW=K11GQS!+\<T^NKC9>;AG.I(L(1D-@6IEKVSI-2]&^O>KM'J
MYYBE*K&T(9;:6SM>92ZQ3+AEH^,A=\<V%F 4PP3<1T;LE1FW$DNE,:8A_<'S
MK%O;<4K+:WLB-9K],L=6(JE,L24!;S#,*L4*4^TAS38[1K>S_X7TAXXE=.F:
M>V^C%%>BR*#WTZ7.[GON8?'//3X%LO7^B\VH'? FVHT=TU.%">R7Q%P2,Q)S
MIVYT>]NJG><BY@-*Q"[O_/#9YD/;H9-/E+XX_V]DA_,"=2]8:-F;1NQ#WI#3
M*@_>QM'="YR$K@K5PJ"0<[P<IWI@FK+;VXS/=RZ%+\\[;[7%8NO_>LMHM7<L
M4BE0;* DNKTBNIK1K>U_J&,/!/Y9)%CH/<)IA)<=]=_I-$*9F]F'TPAE<F8W
M.]*/1')4FWQ7+W-$(>6!E"F;[4FY9]1J.1ZL*;&TT8'+EE&OY6@\O]PJO.(M
M^ D+#/<M")4]7?)01?"(-LVAG4"H@_=>VUH [5DFZB4CN%\S:H7--+Y<$5V\
M!9=;>]%;.R#7\K/GCBNA\*<,3W7Q$%;/',$#$1L23YL>/4Q/I=$WNIWRF$+!
ML=2L&>U>CH6:+R<N?K>ZN$!NRAY2;L-H];=MFES&QY\?2?7]/[M07*$BXQX%
M"GP?FCM<;W6,1F?'Q'%AXATE@M?<^= T:KLV%"L#'J7K_!+#[5<3[HN)YP#Q
M![^J"N*RZ/.!19_%H^,R6+2T9?Q(@/\&R@&9(## I6,S[K,;[D0"F*!_PNHU
M Q:!_U>#&(_"B>?#:RP:K[ZU@P!+&JB2(0J#$/[ V!,/L)UK]N94&K3^#M$R
MX+'9W6>]1KUQ4L:E2C25@2EY@,.;3CUWC3AKU-;(LRVDE9RMT\.2.:/5[=,H
M^%COU^CC8TE%@\$T,V&&]HUP=@O=O^RH3:<.3F]KQR1_&5Q[/C2UC6ZKK#Y]
MCNI36'!H>RYW&%X85+%=9O*9'?+=N@Z];-V._1X[9:5IT;'4-'I;]RTO#;#=
M2MNC:>1PO-O#$B/;M,L#,]M#\;C>J1M@N;PJ#9;"HJA?-^J-5BX8>D&V2DJ<
MJ ,RWG3FBXEP _"(F$TWE)5VR_8:L;/_IY8/'$6-WK9]Q,NS,65&*RZD"#)Y
M+;%[9YSG.&"PC_S9ZC:,1GO'8\V;06*/3+B#0FV[V3.ZW<<^.5(DVZ_HTLM9
MZ.SU:-+L@9U0%'(E3A8;9SV$"?:_@\JC@*;8<F&WWI6/")^"]PDJN>-%<\=.
MS3 +P!VD4U^'V-(-_K7LF[>_P7_TDJ?<']NN7EDO2YBF<$/A*X"__6V($ZF-
M+\ZC8-6L5]LPQ\P+* OSQA<.Q^SNR:UMA1,%RO1SZL6UY!$^! !$X=U'5BXC
M_5^<VK;^>63WFY8U&G;,7G-HMFHCJ]^J=;K=1J=GU88MT6G_;Z-QI!^:^'HY
M,SX6E:$O^/<*'\'>WW#GEL^#[)JG #"UWT:#]KOE4E-SK8+VXY%W_;YFHTU<
M];M/7SX._CB_9)^OSZHKL;P;;6Q.8\^]ZV_GIU\N3S]]_C2X_O3EDGUYSSX,
M!E_9]1=V^>6R0G^__W0Y@"&#S^SB?'#U^[?SJSW<Y_%@*GL[VBX+)UX$<UF!
MP<0/4Z# 0?.3#-&9\/4G^<"K?=SL[RZ/+#L4UD-73T(SD50DI6$7#I\%XHW^
MXT2'86R7UD(/G61?@#)BT0?!]\F?E?CH=ZOU;@,EB/* U(N5<*F2<%G0./*W
M;JO:['=7_ERKUG?\K=UI[_3DNL76:]5F;[=I<UIL;]-I#R%"N*4K_40VV48-
MLI?;8FOVM#($U-]D^U(L/ \ >AL!X'KB"\$N8-PD8.>N):RD[&X#L)1T]-AT
ME/(^MSAP5&PBP_+-38)1FVSXI0%ND[K_O=,0^Q2%78Z9;\+T7--V;(X>)U8K
MDZD?>NS2<Z79SZV_H@ 3\ZX(F>,%#VB5?]\1Q,>^\. )9B_,"@^ 6=:4RG2+
MP30K;N]$MM#<D,<=68<<1UVVQ6+'0X^[-:/5;^QS$5])<'M%</VN46L6B> .
M0!GM;^VD99%%)OLT\6 BXY:5(0^$1764P@VD>:<:D9=UE%L#N6ET.^VRDK+8
M2&K5C'JC<.W[]DXV%F_!AS>R1$'N(TL4Y#ZR1$'N(TL4Y#[RQ<3-5H>4"W71
M_$N(=AQ$(>)QIV-T&]VMXR#%J,$MR?>EDV^[8_3KVX?Q\B#?PFI-/41#MDU,
ME$-2[Y$3@XN5T8>UQ,*24_:1>GLOCXL^7JH_50:KNMNQ(0]LDTID+1N+TZU-
MRP'V!.<[Y@@*;7AG$M8IG*Y&:GGE_4N_??RX7JTU-[=-BI?L*,EMK\BM46UM
MT0>IS-H\*$Q49K1??&.K6K6V;4*[>'5+!XXC4,$YMDH]$,%8O 4?WL@2!;F/
M+%&0^\@2!;F/+%&0^\@7$U5[6-BT[&I5J%#)"^C;<URK]GM;AUC*=E8E6QPV
M6]2KK?8!L$5!+8'-^VT='6AWK?;1VP=WU^HV=NJM]=1MA^YP%+4=NO#.SO%.
M+,99Z'-+ *:_8[[YG>U-^(UPV?5$^'PF(B#Q@'T.K;MMMM:1PK/W4FK@ICZY
M-R((/9^=PE!NAMFT=Q'6O1P9_Q*N:X_ 'OWJ^:9P'+L@Z_K#-@7[ZHO MH0;
M&BR&[S=B9<\-"K+0OQ0 JS,%P%]^ZK1.AHJ69V#E3WG5]*8%6>[_K;/C1JW^
MBC5:O4JMVZH7BD:7\]:%L&R^;XQU87\7[)V8"[\@"[KB4_;.]VY=X"5SE4A]
M[D5- 4I#!!)Q3<"G0UQAP?BE66^\8OU.O=)HUQH[D-Y&)@NI\/P,EM=#SYK#
M/Y-PZKS]_U!+ P04    " #HA:Q6ARU\MW$4  #M?0  $0   &)H=FXM,C R
M,S U,3(N:'1M[3UK<]HXU]_W5^AEY]VGG8E OMNTS3-I(%VZ!=J$EH4O&=F2
M@XFQ6=LDP*]_CF0@(4!"VB8AVW0Z+:"+STWGIB/Y[7_'@Q!=\"0-XNA=02F2
M OKO_MO_P_CO]\>?4"7V1@,>9>@PX33C#%T&60^U&4_/D9_$ ]2.D_/@@F(L
MQQS&PTD2G/4RI!)5N]&8E+FE*42Q&;8=8F)=<7SL,,*QY9NV#VVF1^R]L[*J
M4E7W5!T;GJ]AW?%5[/@^@;Z&96N$<]?V]EC9<KEE*42ENN7KU-8=US,<R_!5
MQ?,4V]3$8WL98 <81FDY&&<XY=Z[0B_+AN52Z?+RL@C?BV?Q12F(PB#B N-2
MEM H]>-D0#.@2$DEBH&)C36ED,^S-/Y2*\;)64EQ'*<T%L^:=2K#=.=+/<=N
M$LJ^*B%:232[-.6%*]C6][X-,)5@HF)%G4_">+"81$XPQPX:1/=%1]$8W )=
M$*49C;P%=.,5;);P%JU7B&R:5]&N(;.8.0W6S0M0**6_ZY].O!X?4+P$3SFD
MT=F[ H_PUY,",)A3MO]VP#.*Q#R8_S,*+MX5#N,H ['%K<D0AGGYMW>%C(^S
MDN13:?^WWWY[FP59R/?=WD6$A< 20U'?EO(?WY;RJ=V83?;?LN "I=DDY.\*
M+$B'(9V4HSCB $ P+HN./,D_!HSQ2'Z$]@:LG23P\N>/LV/NORL$GJGZ3-&)
MK;E$UWS#X9K/F<^Y2CEQ;>6T,@=E 5,!170@'LV#<C4"^":'@$Y"PUK$^/@O
M/BF@@,'43/LV<2OQQ2?U^**CU4>L7[WH?G#ZS3X+NBU/J[<.)IW6%ZW;/^XU
M*U^,SJ"N-%N>TNW7QAVU/FY6.M-/6B/L3&.M,_BJ-:;5R_J@2AIJAW1:9Z39
M_MAOM,ZU1KLSJ;<;_7KK3*TK-OFD=B>=MF<VVM_..^UO8:==U>J5&FE4/)BG
M.JFK7RX;'[XJW4&CUVT=GW<'7R[8AZ/ _?#5K$^KTWJEV^OVPZ ^]93&AP[
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M.LOB: ]5#L&Q-G1GYSEQU#RNHP>TC_.X)/?OGM(\CN?FL:X>!9W^Q_-ZY3B
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M6_RY,O!=9!$*>SU1%MIQ#65\_\$HDP/'N#?S0LK2+1*] ":ZUD3S7)S>/#F
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M)G^7 H!=\?6US;Y^*7]_M7SI]?[_ %!+ P04    " #HA:Q6[$(UN6P"  "
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M5^F/B?VLI0#CX@$4#Z6LZCU.=KZ\=]D:)\_D 9Y7%A.9VEKG)@<5RHO:L&%
M>=KP>U]29YL]\=),Z<S6KXX0'/WOG5+VRU^L_K%)1.-I!&5$J<^ C%A@Q8Q#
MP#%'@!LC: B9#C1J)V9'*R,5] KBR_6#5X#U+N_2ML)V$=M4W#WI&D;@[9GJ
M(/0]3/00N\OKP(+?$]BNZ/<9/Y_PT32B4C*()4"!+4&(3S&@VI> !G9$)X23
M +.^PD=_*>%_3G1_X:,>PF]%U\\4_CZFGD7XZ"C"=ZEE8.&C-L)'/81_F?%B
M,>OB82[2V51% D*D./"IG6<0%OF !XS:NET0:K"T*2!L*O:*Y[$)? 7.6Z)K
M+N<J78<EW)F$(\NV8?RM1.J,M9,PJYX&$Z,S@$T!N@VZCK8?XIG^=#L7.ILB
MJ235#-J:.A" 0!@!@6V)C4AD DE@('G+0?;)^=BDMQHQ"H#>$F';T72#N*:#
M:#<ZAAD[FS#18;3<#;G'(+GA;."Q<3>,W2'18=->E%\R?9;.Y]KB*G9P/BX6
MMSJ[+):_LL_&V+ZFA%90" D$E[829J$=%T-N@%+:1)A'*@@:3X$/-38VT5J\
M0&X ]I:(O25DK\3<7,8'J3XLZ^<D\,@R[\5=*^$W):53(CCH?+#$T#3,S431
M^#/M$\=%.HMEG-O"X'=NM1CSV11'RM=,AW:^3,I),P6,8@&@QD0% B,I<=-4
ML>M^;,GA":&WAM@\%SC8.ZS^?IP<6>]MZ&@E[_JH.PG:X6XP"=>'LBG:/58]
ME[C.[./G[#*]2Z:"!:'R0P8P,1J0B-HY+XPPH C2$"O!_.9:K6EC;(+=7K0I
MD%H>O0)KQZ6M#4);+FQUHVG@9:U&#'5?TMKEH/^"UH;/G[.<M1M4[6*6P[2K
MP#\F,LUNTJP\/G21V[QQEMXF>?9PEBH])8(:K (.8*%XXIL(<$-#(*2((H,0
M@W[43NQ[VQNI\"N87WHEZJ)WKY![!?2V>6 _[TUSPK.Q.4Q^Z$5DAW31B)X>
MJ6.__X'32*-@=U-*LX^U3R_%D<39E^LT6:\]$1RP@+((D( 00 AFMLB'!DBF
M"!%0:49$TURR[7QLB:/$YY4 6R_:[1!W.!GTH>/(RF_!1"N!UX7<2<T[S@:3
M;ET8FSJMM>E9U'])%SF?_2>^*8<<CGPNE0F!IHA;>4(!&+=_2@ZYSR(=1;S;
MB95*,V,3ZG;AN@3K6;2=1G4GLRT+_,Y\#5SC-Z6J>YGO9*)_I5]U^W.*?6=H
MM?6^V[J]_+]G<9[KI%C9NTWBY4\&%E,J AQ&DEB]!P@0C0G@3!;CM"\-0YP9
MJ9HJW]G"V$2_ NE543;7NIO&PS+O3<Z1%=Z2EU;"WAM[)TV[/0XFY[T!;2IY
MOV%[$1>3_W>9YN780NV0+3060!F" 8$L!!2J$ 044JH8C:AN7%1O.AZ;9,L%
MI0)<RV&Y0M9AA7:EX,C";!A]*T&Z0NVDPXJCP>3G@K^I.N?['<26_M#9.['(
M,R[S)AUHTWY,/:C Y?UWC>Q_S]2'7-%VZT053\/U(E< E6[D-.BPZ:GEK1T'
M'A 6EW$^TU.&BI/ 4(,0$UMJ40$!%]P P1#TE0H8\VGC+<\MYV-+WB4H+S4>
MPO\0__36<%ML>FZS=UB(?3@YLA;;TM%NT[,F[FY;GMO.AMOPK FCLMU99]->
MGNO?H5_:CTZ-IL@8 HN5$#L?DO9)(%M8<15AAJC]+])-I;GI>&RR?/SQ?0&N
MN1@K7!T68E<&CBS"9L&WDIXKTDZRJS@:3'(N^)MR<[[?=0GR_?UEQI-%7$R&
MEK]XGC*?&.-# B ,[(@(@^+NAD@"GP2:1($O MU8=G6-C$V"JS6U]_?>$U)O
M";7MTJ.#T:8+C_UX&F;9L15%'98<ZSGHL>#H<#KP<F-]6+N+C7MLV\O\G4T5
MJD@7'V;\:FI\S8F$$: Z"(H#^SX06"A;_(8F])F18=CXAS(5SV,3]",XKT#7
M7,-5N@X+MS,)1U9KP_A;"=09:R=55CT-)D5G )OZ<QMTGV6^OY?7]EO1G^PW
M-:62$2PP!2$4TFI/4L"9,H :B'B@.(7*;SO3W&Q@;!)<8_36(+T"9?O)9H7$
MYA/.KM0<69@M6>DTYW2%WFO>67$X^-S3%8YK_NFTZUH8?]57<;':E.1EO_,%
MY]H*U$HVM$4Q4PCPP ^ AIC+B!@?L<9[<ZX&QB;>5;7W!+*E>)TD-JV#NU,S
M3 W<E)4.Y:\[]!ZE[Y;#@<M>=SB[)6^-7>=9[5QG5W%R]5N6WN779^G\AB</
MTP@J(\(0 3\4U [  A570@@0A)JK@&'$9=!R8NMJ9Z127F/UEF"]%=K6TULG
MM8UGN'T)&VB2VY*K+O/<?4STF>HZ_0X]V]T7G&/"N]>\Y^FZ\BCMY^Q+EOZ(
M+?RI0"946(= $]\46<  CFQ5+DQQ+:D6VM?=+H;9:FBD:>#QV-CCH>\UX(YG
M[+;Y;9H*^K,V3"[H0%CWDW8U;/0_:[?M^.><MJL)K_:\79U]]XVEQUL]?[6>
MI]1.NU5@?!!2J &AW%8$/-0@$CZ",F0Z#!M7]<X6QI8$'G=;EB@]"],K<+;?
M=:H2V7S[J3,]0^U#-66FTY:4,_I>>U-5CX-O4CD#<NU6N0U[7W>Q>?L""D/*
MC!4RHY$/2!12JV:A #015LAPA73CHQSUS8Q-TCO7-#S+W1:];K7XB]QG<?2+
M+(YTA<48+J]H=VU%FPLK-K^)<_MT^F+]2KR\$?_TQ?\!4$L#!!0    ( .B%
MK%:KF2S[T@8  /,R   5    8FAV;BTR,#(S,#4Q,E]P<F4N>&ULU9M9<]LX
M$L??_2FTVM=M"S<!5^PIKR?92JUGXDH\E:E]8>%H2*Q(I(JDKV^_(&U/XB,S
M7%-;9EYTD""[\>^?@$83>O/3]68]N\2Z*:KR<$[WR7R&I:]"42X/Y[^=OP,]
M_^EH;^_-WP!^_^?'T]G/E;_88-G.3FJT+8;95=&N9I\#-E]FL:XVL\]5_:6X
MM !'_44GU?:F+I:K=L8(XX_/U@>8<4JH#J -42"HB6 "0<BBTC&=4Y[H?RP/
M&+-,>"9 ^LA!F,C Q$A26YEI3A"=]OU-UT7YY:![<;;!6>I<V?1?#^>KMMT>
M+!975U?[UZY>[U?U<L$(X8O[UO.[YM=/VE_QOC4UQBSZLW\T;8KG&J;;TL7O
MOYQ^\BO<6"C*IK6E[PPTQ4'3'SRMO&U[S?_2K]EW6W3?X+X9=(> ,N!T_[H)
M\Z.]V>Q6CKI:XT>,L^[]MX_O'YAT1;6REUAN5[;>V'U?;19=L\5)E:!(#O<W
M:&^V>#AOBLUVC??'5C7&P[E;79;0199(RCJS?[^]</'5^K;&)@'3]_8T';B[
MOK/R4D_PNL4RX&T?[^VL*_^@T;I3N/KCRK5UN.Z/Y@&+O+_KL6O:VOHVYQB-
MS1)"U(0(PDH"%HT%A\%IBADQ5#_L>.=XDSSO ]*@WU]6EXMTXQ08QKH/G2JW
MBCPQ=ZO.R_R^__V=I[:YL<KJZ-*O17$!PF4"'$,-D7HKHP\>M1KE]K?6'GK]
M;52/:S^KZH!U&D#NS=G:/XGP0WCO6BRVMDXW K\JUN'^ZFXDV46LVFH'RMV&
M);D[GZ5>1ZQK#*>W4?ENY_J>M6E8Q;[EF(B_+=NBO?F(RZ(3H&Q_M1O,46J3
M4:= "4E!2./!B8R"=EH%H10G3HR*_'-6!Q' IDO :"5?F81[@L^P+JKPM@P_
MIQDXYUI'K4SR&(D$$9D'PUTW25(K*"K"6=S)(/# [" 6^'19&*_E)(:%]RE7
MJ[=5W2O_*04 3ZJ+LJUO3JJ N1)>!Y*R*4&,ZSJ1.J:5!BD,L4')S-!Q\\,
M)P:!(J8+RJYUG@0V[XHU_GJQ<5CGF95:$H; G4B@NZ# QB# &J>8BLXJ0W;
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M-3$R+GAS9%!+ 0(4 Q0    ( .B%K%;E5KU9F0H  -]@   5
M  "  ==%  !B:'9N+3(P,C,P-3$R7VQA8BYX;6Q02P$"% ,4    " #HA:Q6
MJYDL^](&  #S,@  %0              @ &C4   8FAV;BTR,#(S,#4Q,E]P
<<F4N>&UL4$L%!@     %  4 4 $  *A7      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
